|
Post by nateb on Sept 26, 2018 22:08:09 GMT
|
|
|
Post by nateb on Oct 26, 2018 18:18:29 GMT
If anyone is still following this one: management disclosed today in a webcast that there would be clinical data readouts on their PHIII trial and lead Phase II trial at ASH this year.
|
|
|
Post by JHam on Oct 27, 2018 3:19:30 GMT
If anyone is still following this one: management disclosed today in a webcast that there would be clinical data readouts on their PHIII trial and lead Phase II trial at ASH this year. I haven't been following anymore. Worth taking a look?
|
|
|
Post by nateb on Oct 28, 2018 17:30:15 GMT
JHam,
I think so, their phase 3 candidate is on track for approval for 2020. CEO is looking to partner their phase 2 candidate in multiple indications. If you aren't wanting to invest long term, then at very least it may be good for a run up into data at ASH this year. ASH is in December and abstract titles should public in early November. Also dilution overhang is minimal now, they just announced a funding agreement with our old friends at Lincoln Capital. There are some pretty thorough anti shorting provisions in the agreement, so it looks like management is being cautious(rightfully so) with LC.
|
|
|
Post by nateb on Nov 2, 2018 17:40:06 GMT
ir.actiniumpharma.com/press-releases/detail/302/actinium-pharmaceuticals-ash-annual-meeting-presence-toAll patients receiving Iomab-B therapy in both the study arm and those that crossed over from the control arm achieved engraftment following bone marrow transplant despite high bone marrow blast counts - 88% of patients in the control arm failed to achieve a complete response with 65% of eligible patients in the control arm crossing over to receive Iomab-B - Preliminary safety analysis demonstrates the feasibility of targeted conditioning with Iomab-B for relapsed or refractory AML patients who have active disease and a high bone marrow blast burden I Thought the Phase III results they just announced were pretty impressive, big takeaway is that all(100%) patients receiving bone marrow conditioning with Iomab are successfully engrafting following bone marrow transplant. I don't see how this wont be approved if they keep posting these kind of numbers. There is an argument to be made here once they reach 50% enrollment they should end the trial early and file for approval assuming these kind of numbers. Moreover, they were selected for an oral presentation at ASH. Stock seems to be dragging still due to the enrollment pace. I think that this company is undervalued though.
|
|
|
Post by nateb on Feb 22, 2019 1:17:30 GMT
|
|
|
Post by nateb on Feb 25, 2019 19:32:35 GMT
|
|